Headquartered in Oxford, UK, MitoRx is working on orally delivered mitochondrial protective therapeutics targeting mitochondrial dysfunction linked to the progression of conditions such as Duchenne muscular dystrophy and Huntington’s disease, along with other neurodegenerative diseases. The company says the new funding will be allocated towards its preclinical work in Huntington’s disease, activating its first neurodegenerative disease program, and exploring research collaborations and partnerships.

MitoRx anticipates delivering preclinical results in Duchenne muscular dystrophy, Huntington’s disease, and COPD next year.

“Interim results in our Duchenne program demonstrate that our muscle-penetrative lead asset preserves strength in oxidative muscle, and confirms mitochondrial modulation,” said Dr Christine Charman, Chief Development Officer at MitoRx. “These results will be presented at the Muscular Dystrophy Association Clinical and Scientific Conference in Orlando during March 2024.”

Progression independent of relapse activity (PIRA) has been increasingly recognized in people with multiple sclerosis (MS; NEJM JW Neurol May 24 2022 and JAMA Neurol 2022; 79:682). To learn more about PIRA, investigators used data from the Italian MS Register on 16,130 patients with relapsing-remitting MS, including 1,383 with pediatric-onset MS (POMS; median age at onset, 16), 14,113 with adult-onset MS (AOMS; median age at onset, 29), and 634 with late-onset MS (LOMS; median age at onset, 52).

Compared with patients with POMS, patients with LOMS had the highest incidence of PIRA (hazard ratio

---

, 2.98), followed by those with AOMS (HR, 1.42). Compared with the POMS patient group, the LOMS patient group had the lowest risk for relapse-associated worsening (HR, 0.69), followed by the AOMS group (HR, 0.88). Cumulative PIRA incidence was 1.3% of patients at age 20 years, increased rapidly between ages 21 and 30 (9%), and rose progressively from 40 to 70 (from 22% to 79%). Cumulative incidence of relapse-associated worsening showed a different pattern of increases over time (e.g., 0.5% at age 20; 7.8% at age 40; 14.4% at age 50; 24.1% at age 60; 27.7% at age 70).

These authors provide data supporting the notion that MS pathophysiology is different between patients with PIRA and those with relapse-associated worsening. While relapse-associated worsening seems to increase gradually and reach a plateau, PIRA begins in the 20s and continues to increase. PIRA encompasses accumulating neurodegenerative processes, supporting the concept that a subset of patients experience progression even within the relapsing-remitting phase of the disease.

People may be more than two times likelier to develop schizophrenia-related disorders if they owned cats during childhood than if they didn’t:

---

Living with cats as a child has once again been linked to mental health disorders, because our furry friends apparently can’t catch a break.

In a new meta-analysis published in the journal Schizophrenia Bulletin, Australian researchers identified 17 studies between 1980 and 2023 that seemed to associate cat ownership in childhood with schizophrenia-related disorders — a sample size narrowed down from a whopping 1,915 studies that dealt with cats during that 43-year time period.

As anyone who’s read anything about cats and mental health knows, there is a growing body of evidence suggesting that infection from the Toxoplasma gondii parasite, which is found in cat feces and undercooked red meat, may be linked to all sorts of surprising things. From mental illness to an interest in BDSM or a propensity for car crashes, toxoplasmosis — that’s the infection that comes from t. gondii exposure — has been thought of as a massive risk factor for decades now, which is why doctors now advise pregnant people not to clean cat litter or eat undercooked meat.